News

Opthea Appoints US-Based Non-Executive Director

10 September 2020 The directors of Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, are pleased to announce the appointment of Mr Daniel Spiegelman as an…

Locked And Loaded: Using Genomic Sequencing To Target Covid-19’s Weak Spots

10 September 2020 Originally published via the University of Melbourne by Stephanie Portelli, Elston D’Souza and Associate Professor David Ascher COVID-3D, a new open-access tool harnesses SARS-CoV-2 genomic and structural information to help ensure therapeutic efforts remain effective.…

Noxopharm Appoints New Chair

10 September 2020 Release date 9 September 2020 Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) announces the appointment of Mr Fred Bart as Non-Executive Chair, allowing ExecutiveChair and CEO, Dr Graham Kelly, to focus on the CEO…

Local Response Units And Boosted Reporting For Safe Next Steps

10 September 2020 Release date 8 September 2020 New Suburban Response Units will be set up to give rapid local insights and leverage community connections to help keep localised outbreaks contained, as Victoria takes the first steps to…

Global CRO To Execute Noxopharm DARRT-2 Prostate Cancer Study

10 September 2020 Release date 8 September 2020 Australian clinical-stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that after a rigorous global search, the clinical research organisation (CRO), Parexel® Biotech, has been appointed to manage…

Allens: Capturing the hydrogen opportunity for Australia and Japan

10 September 2020 Now is the time to look for future global opportunities Australia’s hydrogen industry is expected to contribute at least $11 billion to the national economy and generate around 7,600 jobs by 2050. In the current state of play,…

New drug shown to improve bone growth in children with achondroplasia in global phase III trial

10 September 2020 Release date 4 September 2020 A phase three global clinical trial led by the Murdoch Children’s Research Institute (MCRI) has shown a new drug boosts bone growth in children born with achondroplasia, the most common type of…

New AusBiotech industry Advisory Group Chairs appointed

10 September 2020 Release date 3 September 2020 AusBiotech welcomes its new industry Advisory Group Chairs: Dr Megan Robertson, St Vincent’s Hospital Melbourne, Chair of the AusBiotech Clinical Trials Adivsory Group; and Dr Amanda Gillon, Bioscience Managers, Chair…

Cynata Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study

7 September 2020 Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced positive efficacy data from a study of its induced pluripotent stem cell (iPSC)-derived Cymerus™ mesenchymal…

Victorian Government Grant for PolyNovo Hernia Plant

7 September 2020 PolyNovo is pleased to announce it has received a grant from the Victorian Government, Department of Jobs, Innovation and Trade for up to $252,000. This funding is to support the purchase of equipment and the…

CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia

7 September 2020 Heads of Agreement signed between CSL and the Australian Government to supply 51 million doses of University of Queensland vaccine to Australia, with first doses scheduled for release from mid-2021 following successful clinical trials. Heads…

Snoretox receives “Barrier to Innovation” Waiver from FDA (Center for Veterinary Medicine) for Innovative Medical Breakthrough Therapy.

Date Posted: 7 September 2020 4 September 2020 Drug Solution for Hypotonic Muscle Disorders. Snoretox receives “Barrier to Innovation” Waiver from FDA (Center for Veterinary Medicine) for Innovative Medical Breakthrough Therapy. Snoretox Pty Ltd has invented and patented…

Home

News & opinion

Member Directory

Events